Drug Trial Radar · NCT07614477
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Dec 31, 2028
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Everest Medicines (China) Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at \~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.
Conditions
- Minimal Change Disease (MCD)
- IgA Nephropathy (IgAN)
- Focal Segmental Glomerulosclerosis (FSGS)
Interventions
EVER001Drug
EVER001 200 mg, oral administration, twice daily (bid), for the treatment of proteinuric glomerular diseases including FSGS , MCD , and IgA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in 24-hour urine protein-to-creatinine ratio (UPCR)Time frame: Week24
- Treatment-emergent adverse events (TEAEs)Time frame: Throughout the study period, up to Week 56
- Adverse events of special interest (AESIs)Time frame: Throughout the study period, up to Week 56
- Systolic blood pressure change from baselineTime frame: Throughout the study period, up to Week 56
- Body weight change from baselineTime frame: Throughout the study period, up to Week 56
- Change from baseline in clinical laboratory safety parametersTime frame: Throughout the study period, up to Week 56
- Physical examination findingsTime frame: Throughout the study period, up to Week 56
- Chest radiography findingsTime frame: Throughout the study period, up to Week 56
- 12-lead electrocardiogram (ECG) findingsTime frame: Throughout the study period, up to Week 56
- Pulse rate change from baselineTime frame: Throughout the study period, up to Week 56
- Diastolic blood pressure change from baselineTime frame: Throughout the study period, up to Week 56
- Body temperature change from baselineTime frame: Throughout the study period, up to Week 56
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Tianjin Medical University General Hospital
Tianjin, Hebei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.